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Abstract 
The diastereoselectivity of the nucleophilic epoxidation of 3-hydroxy-2-methylene esters has been studied. The 3-
hydroxy-2-methylene esters were obtained through a Morita-Baylis-Hillman reaction. The resulting epoxyesters were 
treated with thiophenol for transformation into 2,3-dihydroxy-2-((phenylthio)methyl) which upon treatment with 
triphosgene afforded the corresponding cyclic carbonates. 
 
Introduction  
Stereoselective synthesis of α,β-epoxyesters is of considerable synthetic interest because a number of 
compounds can be obtained by the opening of the oxirane ring.1-9 A convenient method for the preparation of α,β-
epoxyesters is via nucleophilic epoxidation of chiral α,β-unsaturated esters.2 We previously reported that the 
nucleophilic epoxidation of γ-hydroxy-α,β-unsaturated esters8 (Scheme 1) is a diastereoselective reaction that favor 
                                                 













the syn isomer. We have also reported that the stereoselectivity depends highly on the substitution of the double bond 
and that high syn stereoselectivity (dr >19:1) is observed for the α-methyl-substituted enoates9 (Scheme 1). Free 
hydroxyl group resulted to be key for the control of the stereoselectivity. The nucleophilic epoxidation of methyl 2-
methylene-3-tert-butyldimethylsilyloxycarboxylate esters has been recently reported by A. Myers to get the anti 
diastereomer with high selectivity12 (Scheme 1). The epoxidation of Morita-Baylis-Hillman adducts is an interesting 
transformation because the resulting epoxides can be used in the total synthesis of interesting natural products.10-12 



























α-methylene-β-silyloxy carboxylate esters  
Scheme 1. Stereoselective nucleophilic epoxidations of unsaturated esters. 
 
 
Results and discussion 
We wanted to study the selectivity of epoxidation of 3-hydroxy-methylene carboxylate esters with a range of 
R alkyl and aryl groups (Scheme 2). For the preparation of the substrates, a comparison of different experimental 
procedures was performed as shown in Table 1. Most of the substrates were prepared in good yield using DABCO as 
a base and a (1:1) mixture of dioxane:water as reported.13 We obtained higher yields when the reaction was 













obtained in best yields under solvent-free conditions and longer period of time, and compounds 1m and 1n were 






1a, R = Me
1b, R = Et
1c, R = n-Pr
1d, R = i-Bu
1e, R = Chx
1f, R = CH2CH2Ph
1g, R = CH=CHPh
1h, R = Ph
1i, R = p-Tol
1j, R = p-MeOPh
1k, R = p-FPh
1l, R = p-ClPh
1m, R = m-ClPh
1n, R = o-ClPh
1o, R = p-BrPh
1p, R = o-NO2Ph
1q, R = m-NO2Ph
1r, R = p-NO2Ph
1s, R = Furfuryl
DABCO
 








TABLE 1. Preparation of esters 1. 
 
Entry Substrate Conditions Yield 
1 1a DABCO, dioxane:H2O (1:1), 10M, 48h, rt 99 
2 1b DABCO, dioxane:H2O (1:1), 10M, 48h, rt 70 
3 1c DABCO, dioxane:H2O (1:1), 10M, 48h, rt 99 
4 1d DABCO, dioxane:H2O (1:1), 10M, 48h, rt 85 
5 1e DABCO, dioxane:H2O (1:1), 10M, 48h, rt 81 
6 1f DABCO, dioxane:H2O (1:1), 10M, 48h, rt 99 
7 1g DABCO, dioxane:H2O (1:1), 10M, 48h, rt 99 













9 1i DABCO, solvent-free  4 days, rt 82 
10 1j DABCO, solvent-free  5 weeks, rt 77 
11 1k DABCO, dioxane:H2O (1:1), 10M, 36h, rt 99 
12 1l DABCO, solvent-free  5 days, rt 94 
13 1m DABCO, DMSO 7M,  4 days, rt 99 
14 1n DABCO, DMSO 7M,  4 days, rt 99 
15 1o DABCO, dioxane:H2O (1:1), 10M, 36h, rt 89 
16 1p DABCO, dioxane:H2O (1:1), 10M, 16h, rt 95 
17 1q DABCO, dioxane:H2O (1:1), 10M, 16h, rt 87 
18 1r DABCO, dioxane:H2O (1:1), 10M, 3h, rt 83 
19 1s DABCO, dioxane:H2O (1:1), 10M, 20h, rt 85 
  
 
Esters 1 were epoxidized using lithium tert-butylperoxide (2 equivalents) as the oxidizing reagent in THF as 
solvent at -20 ºC.2,8,9 Table 2 shows that the 2 syn isomer was the major product in all cases. For the aliphatic series 
(compounds 1a-f), the higher steric volume of the R pendant alkyl group the higher stereoselectivity is observed 
(entries 1-6). When the R is an alkenyl group then the epoxidation reaction is not stereoselective (entry 7). 













TABLE 2. Epoxidation of compounds 1. 
 













1 Me 67/33 72 
2 Et 76/24 70 
3 n-Pr 81/19 79 
4 i-Bu 81/19 71 
5 Chx 92/8 85 
6 PhCH2CH2 77/23 59 
7 PhCH=CH 53/47 47 
8 Ph 93/7 68 
9 p-Tol 89/11 82 
10 p-MeOPh 92/8 73 
11 p-FPh 90/10 65 
12 p-ClPh 84/16 52 
13 m-ClPh 92/8 38 
14 o-ClPh 92/8 52 
15 p-BrPh 90/10 68 
16 o-NO2Ph 83/17 43 
17 m-NO2Ph 80/20 60 
18 p-NO2Ph 91/9 65 
19 Furfuryl 93/7 69 
a Isolated yield of products corresponds to mixtures of syn and anti diastereomers. 
  
 We also epoxidized compound 1h by using oxidants other than lithium tert-butylperoxide (Table 3). If the 
reaction was carried out using tert-butyl hydrogenperoxide in the presence of substoichiometric amount of base (entry 
1), then a slightly lower selectivity was observed compared to the reaction carried out using a stoichiometric amount 
of oxidant (entry 8, Table 2). Lithium cumylperoxide gave similar result to lithium tert-butylperoxide (entry 2). On 
the other hand, in the alkaline peroxides series, potassium gave poorer stereoselectivity than either lithium or sodium 













increased at higher temperature (entry 4), affording the syn isomer as the major one. When m-CPBA was used in the 












TABLE 3. Epoxidation of compound 1h. 
 
Entry Conditionsa 2h/3h Yield (%)b 
1 TBPLi   88/12 66 
2 CMPLi   91/9 72 
3 mCPBA   90/10 28 
4 mCPBA   88/12 80 
5 mCPBA   - NR 
6 TBPNa  85/15 41 
7 TBPNa  87/13 62 
8 TBPK  83/17 61 
a For entry 1: 1.5 equiv of TBHP, 0.8 equiv of MeLi, THF, -20 ºC, 20 h. For entry 2: 1.5 equiv of CMHP, 1.1 equiv of MeLi, THF, -20 ºC, 20 h. For entry 3: 2.1 equiv of 
mCPBA, DCM, rt, 96 h. For entry 4: 2.1 equiv of mCPBA, 70 ºC (sealed tube), 96 h. For entry 5: 2.5 equiv of mCPBA, 1.3 equiv of K2CO3, DCM, rt, 96 h. For entry 6: 2.0 
equiv of TBHP, 1.0 equiv of t-BuONa, THF, 0 ºC, 3 h. For entry 7: 2.0 equiv of TBHP, 0.25 equiv of t-BuONa, THF, 0 ºC, 3 h. For entry 8: 2.0 equiv of TBHP, 0.25 equiv of t-






The stereochemistry of epoxides 2b and 2h was confirmed by comparison with already reported data.12,15 The 
epoxyesters 2d, 3d, 2e and 3e were transformed into cyclic carbonates through a one-pot sequence: treatment with 
thiophenol in the presence of a base which resulted in the opening of the oxirane ring and then addition of 
triphosgene to give carbonates 4, 5, 6 and 7, respectively (Scheme 3). The stereochemical assignment of the 
carbonates was performed by NOE experiments (Scheme 3). Carbonates 4 and 6 gave NOE between H-5 and methyl 
















1. NaSPh, THF, 1.5 h, 0ºC

















































1. NaSPh, THF, 1.5 h, 0ºC















 In summary, the diastereoselectivity of the nucleophilic epoxidation of 3-hydroxy-2-methylene esters has been 
studied. The syn isomer was the major one in all cases. The resulting 3-hydroxy 2-epoxyesters were treated with 
thiophenol for transformation into 2,3-dihydroxy-2-((phenylthio)methyl) which upon treatment with triphosgene 
afforded the corresponding cyclic carbonates. 
 
Experimental Section 
General Experimental Methods. All solvents used in reactions were freshly distilled from appropriate drying agents 
before use.   1H NMR spectra and 13C NMR spectra were measured in CDCl3 (1H, 7.24 ppm; 13C 77.0 ppm) solution 
at 30 °C on a 300 MHz or a 500 MHz NMR spectrometer. IR spectra were recorded as oil films or KBr discs or NaCl 













performed with precoated plates (Kieselgel 60, F254, 0.25 mm). Unless otherwise specified, all reactions were carried 
out under argon atmosphere with magnetic stirring.  
General experimental procedure for the preparation of compounds 1a-s: 
To a solution of aldehyde (1 mmol) in dioxane-water (1:1) (0.1 mL) was added methyl acrylate (3 mmol) and 
DABCO (1 mmol). The reaction was monitored by TLC. Upon completion, water (70 mL) was added and poured 
onto a separatory funnel and extracted with ethyl ether or dichloromethane (3 x 30 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The crude was purified through chromatography (silica-
gel, hexanes/ethyl acetate (8:2), (6:4)) to afford the desired compound. 
 
Methyl 3-hydroxy-2-methylenebutanoate 1a.16 1H NMR (500 MHz, CDCl3) δ 6.19 (1H, s), 5.81 (1H, s),  4.59 (1H, 
q, J = 6.5 Hz), 3.76 (3H, s), 2.61 (1H, br s), 1.36 (3H, d, J = 6.5 Hz).13C NMR (125 MHz, CDCl3)?δ?167.1, 143.6, 
124.0, 67.2, 51.8, 22.1 ppm.  
Methyl 3-hydroxy-2-methylenepentanoate 1b.17 1H NMR (500 MHz, CDCl3) δ 6.22 (1H, s), 5.78 (s, 1H), 4.31 
(1H, t, J = 7.0Hz), 3.76 (3H, s), 2.43 (1H, br s), 1.73-1.61 (2H, m), 0.93 (3H, t, J = 7.4Hz). 13C NMR (125 MHz, 
CDCl3)?δ?167.0, 142.3, 124.7, 72.0, 51.5, 29.0, 10.0 ppm.  
Methyl 3-hydroxy-2-methylenehexanoate 1c.18 1H NMR (500 MHz, CDCl3) δ 6.20 (1H, s), 5.78 (1H, s), 4.38 (1H, 
t, J = 6.5 Hz), 3.76 (3H, s), 2.41 (1H, br s), 1.63-1.58 (2H, m), 1.49-1.45 (1H, m), 1.31-1.38 (1H, m), 0.90 (3H, t, J = 
6.7 Hz). 13C NMR (125 MHz, CDCl3)?δ?167.0, 142.5, 124.7, 71.3, 52.0, 38.5, 19.0, 14.0 ppm.  
Methyl 3-hydroxy-5-methyl-2-methylenehexanoate 1d.18 1H NMR (500 MHz, CDCl3) δ 6.18 (1H, s), 5.78 (1H, s), 
4.45 (1H, dd, J = 8.5, 4.3Hz), 3.76 (3H, s), 2.40 (1H, br s), 1.80-1.75 (1H, m), 1.58-1.51 (1H, m), 1.44-1.38 (1H, m), 
0.92 (6H, m). 13C NMR (125 MHz, CDCl3)?δ?167.0, 142.8, 124.6, 71.3, 69.9, 51.9, 45.5, 24.8, 23.3, 21.8 ppm.  
Methyl 2-(cyclohexyl(hydroxy)methyl)acrylate 1e.19 1H NMR (500 MHz, CDCl3) δ 6.23 (1H, s), 5.71 (1H, s), 4.06 
(1H, d, J = 7.2 Hz), 3.76 (3H, s), 2.44 (1H, br s), 1.94 (1H, m), 1.50-1.76 (5H, m), 1.24-0.92 (5H, m). 13C NMR (125 













Methyl 3-hydroxy-2-methylene-5-phenylpentanoate 1f.20 1H NMR (500 MHz, CDCl3) δ 7.30-7.17 (5H, m), 6.24 
(1H, s), 5.81 (1H, s), 4.42 (1H, dd, J = 7.5, 5.7Hz), 3.77 (3H, s), 2.85-2.79 (1H, m), 2.73-2.69 (1H, m), 2.42 (1H, br 
s), 2.00-1.95 (1H, m). 13C NMR (125 MHz, CDCl3)?δ?167.0, 141.8, 128.5, 125.9, 125.0, 70.1, 51.8, 38.0, 32.0 ppm.  
(E)-methyl 3-hydroxy-2-methylene-5-phenylpent-4-enoate 1g.19 1H NMR (500 MHz, CDCl3) δ 7.39-7.22 (5H, m), 
6.67 (1H, d, J = 16.0Hz), 6.29 (2H, m), 5.91 (1H, s), 5.13 (1H, m), 3.78 (3H, s), 2.97 (1H, br s). 13C NMR (125 MHz, 
CDCl3)?δ?166.7, 141.3, 136.5, 131.5, 129.2, 128.5, 127.8, 126.6, 125.8, 72.1, 52.0 ppm.  
Methyl 2-(hydroxy(phenyl)methyl)acrylate 1h.18 1H NMR (500 MHz, CDCl3) δ 7.38-7.26 (5H, m), 6.33 (1H, s), 
5.83 (1H, s), 5.56 (1H, s), 3.72 (3H, s). 13C NMR (125 MHz, CDCl3)?δ?166.7, 142.3, 141.6, 128.3, 127.7, 126.8, 
125.6, 72.7, 51.8 ppm.  
Methyl 2-(hydroxy(p-tolyl)methyl)acrylate 1i.18 1H NMR (300 MHz, CDCl3) δ 7.26 (2H, d, J = 8.0Hz), 7.15 (2H, 
d, J = 8.0Hz), 6.32 (1H, s), 5.85 (1H, s), 5.53 (1H, s), 3.71 (3H, s), 2.34 (3H, s). 13C NMR (125 MHz, CDCl3)?δ?
166.8, 142.1, 138.4, 137.5, 129.1, 126.5, 125.8, 73.1, 51.9, 21.1 ppm.  
Methyl 2-(hydroxy(4-methoxyphenyl)methyl)acrylate 1j.20 1H NMR (300 MHz, CDCl3) δ 7.28 (2H, d, J = 8.8Hz), 
6.86 (2H, d, J = 8.7Hz), 6.31 (1H, s), 5.84 (1H, s), 5.52 (1H, s), 3.79 (3H, s), 3.71 (3H, s). 13C NMR (75 MHz, 
CDCl3)?δ?166.8, 159.2, 142.2, 133.5, 127.9, 125.5, 113.8, 72.7, 55.2, 51.9 ppm. 
Methyl 2-((4-fluorophenyl)(hydroxy)methyl)acrylate 1k.20 1H NMR (500 MHz, CDCl3) δ 7.33 (2H, dd, J = 8.5, 
5.5Hz), 7.01 (2H, t, J = 8.7Hz), 6.32 (1H, s), 5.82 (1H, s), 5.53 (1H, s), 3.73 (3H, s), 3.02 (1H, br s). 13C NMR (125 
MHz, CDCl3)?δ?166.6, 162.3 (d, J = 245Hz), 141.9, 137.0, 128.3 (dd, J = 7.2, 21.3Hz), 126.0 (dd, J = 15.0, 21.3Hz), 
115.2 (dd, J = 12.5, 22.5Hz), 72.6, 52.2 ppm.  
Methyl 2-((4-chlorophenyl)(hydroxy)methyl)acrylate 1l.18 1H NMR (500 MHz, CDCl3) δ 7.54 (1H, m), 7.34 (1H, 
m), 7.21-7.30 (2H, m), 6.32 (1H, s), 5.97 (1H, s), 5.58 (1H, m), 3.76 (3H, s), 3.26 (1H, br s). 13C NMR (125 MHz, 













Methyl 2-((3-chlorophenyl)(hydroxy)methyl)acrylate 1m.20 1H NMR (500 MHz, CDCl3) δ 7.37 (1H, s), 7.26 (3H, 
m), 6.34 (1H, s), 5.83 (s, 1H), 5.51 (1H, s), 3.72 (s, 3H), 3.03 (1H, br s). 13C NMR (125 MHz, CDCl3)?δ?166.5, 143.4, 
141.4, 134.4, 129.7, 127.9, 126.7, 126.6, 124.7, 72.7, 52.0 ppm.  
Methyl 2-((2-chlorophenyl)(hydroxy)methyl)acrylate 1n.20 1H NMR (500 MHz, CDCl3) δ 7.54 (1H, m), 7.34 (1H, 
m), 7.21-7.30 (2H, m), 6.32 (1H, s), 5.97 (1H, s), 5.58 (1H, m), 3.76 (3H, s), 3.25 (1H, br s). 13C NMR (125 MHz, 
CDCl3)?δ?166.9, 140.9, 134.5, 132.8, 128.9, 128.1, 127.0, 126.8, 68.9, 52.0 ppm.  
Methyl 2-((4-bromophenyl)(hydroxy)methyl)acrylate 1o.20 1H NMR (300 MHz, CDCl3) δ 7.47 (2H, m), 7.25 (2H, 
m), 6.33 (1H, s), 5.82 (1H, s), 5.51 (1H, m), 3.73 (3H, s), 3.04 (1H, br s). 13C NMR (75 MHz, CDCl3)?δ?166.4, 141.9, 
140.6, 131.4, 128.6, 125.9, 121.6, 71.9, 51.9 ppm.  
Methyl 2-((2-nitrophenyl)(hydroxy)methyl)acrylate 1p.18 1H NMR (500 MHz, CDCl3) δ 7.95 (1H, dd, J = 8.2, 
1.3Hz), 7.75 (1H, dd, J = 7.9, 1.3Hz), 7.64 (1H, td, J = 7.7, 1.3Hz), 7.46 (1H, td, J = 8.5, 1.4Hz), 6.37 (1H, s), 6.20 
(1H, s), 5.73 (1H, s), 3.73 (3H, s), 3.35 (1H, br s). 13C NMR (75 MHz, CDCl3)?δ?163.8, 145.6, 138.5, 133.7, 130.8, 
126.3, 126.0, 123.7, 121.9, 64.7, 49.5 ppm.  
Methyl 2-((3-nitrophenyl)(hydroxy)methyl)acrylate 1q.18 1H NMR (500 MHz, CDCl3) δ 8.26 (1H, m), 8.14 (1H, 
ddd, J = 8.2, 2.3, 1.2Hz), 7.75 (1H, m), 7.52 (1H, t, J = 7.92 Hz), 6.41 (1H, s), 5.89 (1H, s), 5.63 (1H, s), 3.75 (3H, s), 
3.25 (1H, br s). 13C NMR (125 MHz, CDCl3)?δ?166.2, 148.3, 143.7, 141.0, 132.8, 129.5, 126.9, 122.8, 121.7, 72.4, 
52.3 ppm.  
Methyl 2-((4-nitrophenyl)(hydroxy)methyl)acrylate 1r.18 1H NMR (500 MHz, CDCl3) δ 8.18 (2H, d, J = 10.9Hz), 
7.56 (2H, d, J = 10.9Hz), 6.38 (1H, s), 5.86 (1H, s), 5.62 (1H, m), 3.73 (3H, s), 3.32 (1H, br s). 13C NMR (125 MHz, 
CDCl3)?δ?166.4, 148.6, 143.7, 141.0, 127.3, 127.2, 123.6, 72.7, 52.2 ppm.  
Methyl 2-(furan-2-yl(hydroxy)methyl)acrylate 1s.18 1H NMR (500 MHz, CDCl3) δ 7.35 (1H, s), 6.37 (1H, s), 6.31 
(1H, m), 6.24 (1H, m), 5.93 (1H, s), 5.57 (1H, s), 3.74 (3H, s), 3.21 (1H, br s). 13C NMR (125 MHz, CDCl3)?δ?166.4, 
154.1, 142.3, 143.7, 139.5, 126.7, 110.4, 107.1, 67.2, 52.0 ppm.  
 













To a  -78 ºC cold THF (3.5 mL) was added TBHP (3.3 M in toluene) (2 mmol) and then methyllithium (1.6M in 
hexanes) (1.7 mmol). The resulting mixture was stirred at -78 ºC for 15 min and then a solution of compound 1 (1 
mmol) in THF (2 mL) was added drop wise and then the mixture was left at -20 ºC (fridge) for 20 h. Then solid 
Na2SO3  (120 mg) was added in one portion and stirred for 15 min, then diluted with water and extracted with Et2O (3 
x 30 mL), the organic layers were washed (brine), dried (Na2SO4), and concentrated. The crude oil was purified 
through chromatography (silica-gel, hexanes/EtOAc (7:3) and (1:1)). 
 
Methyl 2-(1-hydroxyethyl)oxirane-2-carboxylate 2a/3a. (yield= 167 mg, 99%) (Ratio of diastereomers 67/33).  1H 
NMR (500 MHz, CDCl3) δ 4.33 (1H, q, J = 6.6Hz) (minor), 4.16 (1H, q, J = 6.4Hz) (major), 3.71 (3H, s), 3.10 (1H, 
d, J = 5.9Hz) (major), 4.64 (1H, d, J = 6.1Hz) (minor), 2.99 (1H, d, J = 6.0Hz) (minor), 2.96 (1H, d, J = 5.8Hz) 
(major), 2.08 (1H, br s), 1.31 (3H, d, J = 6.4Hz) (major), 1.29 (3H, d, J= 6.6Hz) (minor). 13C NMR (125 MHz, 
CDCl3)?δ?170.0 (minor), 169.9 (major), 65.1 (major), 64.9 (minor), 59.6 (minor), 59.0 (major), 52.5 (major), 52.4 
(minor), 49.3 (minor), 49.2 (major), 18.6 (minor), 18.2 (major) ppm. IR (KBr)?δ?3932, 3839, 2984, 2363, 1738, 1519, 
1382, 1285, 1173, 1095, 971, 913, 853 cm-1. HRMS  m/z calcd. for C6H10O4Na [M+Na+]: 169.0477, found: 169.0478. 
Methyl 2-(1-hydroxypropyl)oxirane-2-carboxylate 2b/3b. (yield= 128 mg, 70%) (Ratio of diastereomers 76/24).  
1H NMR (500 MHz, CDCl3) δ 3.75 (1H, m), 3.71 (3H, s), 3.12 (1H, d, J = 6.0Hz), 2.98 (1H, d, J = 6.0Hz), 2.55 (1H, 
br s), 1.72 (1H, m), 1.48 (1H, m), 0.98 (3H, t, J= 6.7Hz). 13C NMR (125 MHz, CDCl3)?δ?170.0, 71.0, 50.1, 52.5, 49.6, 
26.0, 9.9 ppm. IR (KBr)?δ?3770, 3457, 2939, 2360, 1869, 1637, 1541, 1440, 1348, 1197, 1139, 1055, 950, 758 cm-1. 
HRMS  m/z calcd. for C7H12O4Na [M+Na+]: 183.0633, found: 183.0636.  
(Yield 2c/3c = 99%) 
syn-Methyl 2-(1-hydroxybutyl)oxirane-2-carboxylate 2c. 1H NMR (500 MHz, CDCl3) δ 3.84-3.87 (1H, m), 3.78 
(3H, s), 3.12 (1H, d, J = 5.9Hz), 2.98 (1H, d, J = 5.9Hz), 1.69-1.40 (4H, m), 0.94 (3H, t, J= 7.2Hz). 13C NMR (125 
MHz, CDCl3)?δ?170.0, 69.3, 58.3, 52.4, 49.6, 35.0, 18.7, 13.8 ppm. IR (KBr)?δ?3649, 2960, 2361, 1740, 1560, 1457, 
1382, 1197, 1139, 1077, 983, 760 cm-1. HRMS  m/z calcd. for C8H14O4Na [M+Na+]: 197.0790, found: 197.0786. 
anti-Methyl 2-(1-hydroxybutyl)oxirane-2-carboxylate 3c. 1H NMR (500 MHz, CDCl3) δ 4.12-4.10 (1H, m), 3.78 













13C NMR (125 MHz, CDCl3)?δ?170.0, 69.0, 59.4, 52.5, 49.3, 35.1, 18.9, 13.7 ppm. IR (KBr)?δ?3466, 2960, 1739, 
1639, 1567, 1441, 1356, 1287, 1212, 1197, 1138, 1129, 1036, 982, 957 cm-1. 
(Yield 2d/3d = 71%) 
syn-Methyl 2-(1-hydroxy-3-methylbutyl)oxirane-2-carboxylate 2d. 1H NMR (500 MHz, CDCl3) δ 3.92 (1H, dd, J 
= 3.8, 9.2Hz), 3.78 (3H, s), 3.12 (1H, d, J = 5.9Hz), 2.98 (1H, d, J = 5.9Hz), 1.93-1.86 (1H, m), 1.41-1.51 (2H, m), 
0.95 (6H, t, J= 6.5Hz). 13C NMR (125 MHz, CDCl3)?δ?170.0, 68.0, 58.5, 52.5, 49.6, 41.8, 24.4, 23.5, 21.4 ppm. IR 
(KBr)?δ?3743, 2956, 2361, 1738, 1438, 1368, 1171, 1116, 1078, 994, 919, 864, 758 cm-1. HRMS  m/z calcd. for 
C9H16O4Na [M+Na+]: 211.0946, found: 211.0942. 
anti-Methyl 2-(1-hydroxy-3-methylbutyl)oxirane-2-carboxylate 3d. 1H NMR (500 MHz, CDCl3) δ 4.20 (1H, dd, J 
= 3.8, 9.2Hz), 3.77 (3H, s), 3.09 (1H, d, J = 5.9Hz), 2.98 (1H, d, J = 5.9Hz), 2.06-1.96 (1H, br s), 1.76-1.82 (1H, m), 
1.48-1.51 (1H, m), 1.27-1.35 (1H, m), 0.95 (6H, t, J= 6.5Hz). 13C NMR (125 MHz, CDCl3)?δ?170.0, 67.5, 59.6, 52.5, 
49.3, 42.0, 24.4, 23.5, 21.3 ppm. IR (KBr)?δ?3491, 2957, 2393, 1738, 1440, 1368, 1184, 1115, 1094, 993, 919, 879 
cm-1. 
syn-Methyl 2-(cyclohexyl(hydroxy)methyl)oxirane-2-carboxylate 2e. 1H NMR (500 MHz, CDCl3) δ 3.78 (3H, s), 
3.39 (1H, d, J = 6.7Hz), 3.11 (1H, d, J = 5.9Hz), 2.96 (1H, d, J = 5.9Hz), 2.12 (1H, br s), 1.88 (1H, m), 1.75-1.63 (5H, 
m), 1.26-1.03 (5H, m). 13C NMR (125 MHz, CDCl3)?δ?170.1, 75.1, 57.3, 52.4, 49.7, 41.2, 29.3, 28.2, 26.2, 26.0, 25.8 
ppm. IR (KBr)?δ?3799, 2930, 2669, 2342, 1741, 1377, 1306, 1200, 1124, 1087, 1030, 932, 761 cm-1. HRMS  m/z 
calcd. for C11H18O4Na [M+Na+]: 237.1103, found: 237.1105. 
anti-Methyl 2-(cyclohexyl(hydroxy)methyl)oxirane-2-carboxylate 3e. 1H NMR (500 MHz, CDCl3) δ 3.77 (3H, s), 
3.69 (1H, d, J = 6.5Hz), 3.02 (1H, d, J = 5.9Hz), 2.97 (1H, d, J = 5.9Hz), 1.94 (1H, m), 1.78-1.64 (5H, m), 1.30-0.94 
(5H, m). 13C NMR (125 MHz, CDCl3)?δ?169.8, 74.5, 65.7, 58.7, 52.5, 49.6, 41.5, 29.6, 28.2, 26.1, 25.8, 15.1 ppm. IR 
(KBr)?δ?3752, 2936, 2668, 2341, 1740, 1422, 1232, 1153, 1104, 1069, 1052, 974, 957 cm-1. 
syn-Methyl 2-(1-hydroxy-3-phenylpropyl)oxirane-2-carboxylate 2f. 1H NMR (500 MHz, CDCl3) δ 7.33-7.20 (5H, 













m), 2.20-2.01 (1H, m), 1.82-1.93 (1H, m). 13C NMR (125 MHz, CDCl3)?δ?170.0, 141.5, 128.4, 126.1, 68.9, 58.3, 
52.6, 49.3, 34.8, 31.7 ppm. IR (KBr)?δ?3873, 3063, 3003, 2924, 2364, 1748, 1290, 1240, 1132, 1075, 754, 701 cm-1.  
anti-Methyl 2-(1-hydroxy-3-phenylpropyl)oxirane-2-carboxylate 3f. 1H NMR (500 MHz, CDCl3) δ 7.30-7.17 
(5H, m), 4.11 (1H, d, J = 9.3Hz), 3.76 (3H, s), 3.05 (1H, d, J = 6.0Hz), 3.00 (1H, d, J = 6.0Hz), 2.93-2.87 (1H, m), 
2.75-2.69 (1H, m), 1.99-1.93 (1H, m), 1.89-1.82 (1H, m), 1.54 (1H, br s). 13C NMR (125 MHz, CDCl3)?δ?170.0, 
141.3, 128.4, 126.0, 68.9, 59.1, 52.3, 49.3, 34.5, 31.8 ppm.  
(E)-Methyl 2-(1-hydroxy-3-phenylallyl)oxirane-2-carboxylate 2g/3g. (yield= 103 mg, 47%) (Ratio of 
diastereomers 53/47).   1H NMR (500 MHz, CDCl3) δ 7.40-7.24 (m, 5H), 6.74 (1H, d, J = 16.0Hz) (major and minor), 
6.27 (1H, dd, J = 6.3, 12.0Hz) (major), 6.23 (1H, dd, J = 5.8, 13.2Hz) (minor), 4.85 (1H, dd, J = 6.3, 1.3Hz) (minor), 
4.71 (1H, dd, J = 6.5, 1.2Hz) (major), 3.80 (3H, s) (major), 3.79 (3H, s) (minor), 3.15 (1H, d, J = 5.9Hz) (major), 3.13 
(1H, d, J = 6.1Hz) (minor), 3.06 (1H, d, J = 6.1Hz) (minor), 3.00 (1H, d, J = 5.9Hz) (major). 13C NMR (125 MHz, 
CDCl3)?δ?169.8 (minor), 169.7 (major), 136.2 (minor), 136.1 (major), 133.5 (major), 133.1 (minor), 128.6, 128.1, 
128.0, 126.7 (major and minos), 125.9 (minor), 125.6 (major), 70.7 (major), 70.0 (minor), 59.0 (minor), 58.5 (major), 
52.7, 52.6 (major and minor), 49.9 (major), 49.2 (minor) ppm. HRMS  m/z calcd. for C13H14O4Na [M+Na+]: 
257.0790, found: 257.0792. 
syn-Methyl 2-(hydroxy(phenyl)methyl)oxirane-2-carboxylate 2h.10 1H NMR (500 MHz, CDCl3) δ 7.43-7.30 (5H, 
m), 5.18 (1H, s), 3.73 (3H, s), 3.12 (1H, d, J = 5.9Hz), 2.86 (1H, d, J = 5.9Hz). 13C NMR (125 MHz, CDCl3)?δ?169.7, 
138.4, 128.4, 127.0, 71.7, 59.0, 52.6, 49.7 ppm. IR (KBr)?δ?3487, 3064, 2910, 2359, 1739, 1269, 1160, 1082, 1027, 
947, 757 cm-1. HRMS  m/z calcd. for C11H12O4Na [M+Na+]: 231.0633, found: 231.0632. 
syn-Methyl 2-(hydroxy(p-tolyl)methyl)oxirane-2-carboxylate 2i. 1H NMR (500 MHz, CDCl3) δ 7.29 (2H, d, J = 
8.0Hz), 7.26 (2H, d, J = 8.0Hz), 5.15 (1H, s), 3.72 (3H, s), 3.11 (1H, d, J = 5.9Hz), 2.86 (1H, d, J = 5.9Hz). 13C NMR 
(125 MHz, CDCl3)?δ?169.8, 137.9, 135.5, 128.9, 127.0, 71.4, 59.1, 52.6, 49.6, 21.1 ppm. IR (KBr)?δ?3502, 3005, 














syn-Methyl 2-(hydroxy(4-methoxyphenyl)methyl)oxirane-2-carboxylate 2j. 1H NMR (500 MHz, CDCl3) δ 7.33 
(2H, d, J = 8.8Hz), 6.87 (2H, d, J = 8.8Hz), 5.16 (1H, s), 3.79 (3H, s), 3.67 (3H, s), 3.12 (1H, d, J = 6.0Hz), 2.85 (1H, 
d, J = 6.0Hz). 13C NMR (125 MHz, CDCl3)?δ?169.8, 159.5, 130.4, 128.5, 113.8, 71.2, 59.1, 55.2, 52.6, 49.5 ppm. IR 
(KBr)?δ?3493, 3003, 2910, 1742, 1197, 1124, 1031, 978, 917, 836, 756 cm-1. HRMS  m/z calcd. for C12H14O5Na 
[M+Na+]: 261.0739, found: 261.0738. 
syn-Methyl 2-((4-fluorophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2k. 1H NMR (500 MHz, CDCl3) δ 7.40 
(2H, dd, J = 8.5, 5.5Hz), 7.03 (2H, t, J = 8.7Hz), 5.15 (1H, s), 3.73 (3H, s), 3.13 (1H, d, J = 6.0Hz), 2.85 (1H, d, J = 
6.0Hz). 13C NMR (125 MHz, CDCl3)?δ?169.7, 162.2 (d, J = 245Hz), 134.2, 129.0 (dd, J = 7.2, 21.3Hz), 115.2 (dd, J = 
12.5, 22.5Hz), 71.1, 65.8, 52.7, 49.6 ppm. IR (KBr)?δ?3477, 3070, 2958, 2342, 1737, 1509, 1398, 1271, 1197, 1128, 
1045, 980, 842, 756 cm-1. HRMS  m/z calcd. for C11H11FO4Na [M+Na+]: 249.0539, found: 249.0535. 
syn-Methyl 2-((4-chlorophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2l. 1H NMR (500 MHz, CDCl3) δ 7.37 
(2H, d, J = 8.0Hz), 7.32 (2H, d, J = 8.0Hz), 5.29 (1H, s), 3.73 (3H, s), 3.14 (1H, d, J = 6.0Hz), 2.88 (1H, d, J = 
6.0Hz). 13C NMR (125 MHz, CDCl3)?δ?169.6, 137.0, 134.1, 128.6, 128.5, 71.2, 58.7, 52.7, 49.7 ppm. IR (KBr)?δ?
3518, 3001, 2929, 1723, 1411, 1287, 1160, 1107, 1049, 982, 920, 756 cm-1. HRMS  m/z calcd. for C11H11ClO4Na 
[M+Na+]: 265.0244, found: 265.0245. 
syn-Methyl 2-((3-chlorophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2m. 1H NMR (500 MHz, CDCl3) δ 7.44 
(1H, s), 7.32 (3H, m), 5.10 (1H, s), 3.73 (3H, s), 3.16 (1H, d, J = 6.0Hz), 2.90 (1H, d, J = 6.0Hz). 13C NMR (125 
MHz, CDCl3)?δ?169.6, 140.6, 134.3, 129.6, 128.4, 127.1, 125.3, 71.3, 58.7, 52.8, 49.8 ppm. IR (KBr)?δ?3466, 3020, 
2964, 1736, 1463, 1264, 1154, 1170, 1083, 962, 918, 877 cm-1. 
syn-Methyl 2-((2-chlorophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2n. 1H NMR (500 MHz, CDCl3) δ 7.54 
(1H, m), 7.33 (1H, m), 7.24-7.29 (2H, m), 6.04 (1H, s), 3.82 (3H, s), 3.06 (1H, d, J = 6.0Hz), 2.35 (1H, d, J = 6.0Hz). 
13C NMR (125 MHz, CDCl3)?δ?169.9, 135.0, 132.9, 129.5, 127.9, 126.9, 67.9, 58.6, 52.9, 50.5 ppm. IR (KBr)?δ?
3741, 3019, 2938, 1734, 1472, 1390, 1297, 1195, 1064, 1028, 1028, 758, 741 cm-1.  
syn-Methyl 2-((4-bromophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2o. 1H NMR (500 MHz, CDCl3) δ 7.48 













6.0Hz). 13C NMR (125 MHz, CDCl3)?δ?169.6, 137.5, 131.5, 129.0, 122.2, 71.2, 58.7, 52.7, 48.9 ppm. IR (KBr)?δ?
3711, 3077, 2957, 2360, 1923, 1592, 1728, 1460, 1333, 1286, 1196, 1127, 1049, 935, 755 cm-1. HRMS  m/z calcd. 
for C11H11BrO4Na [M+Na+]: 308.9738, found: 308.9735. 
syn-Methyl 2-((2-nitrophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2p. 1H NMR (500 MHz, CDCl3) δ 7.96 
(1H, dd, J = 8.2, 1.3Hz), 7.79 (1H, dd, J = 7.9, 1.3Hz), 7.65 (1H, td, J = 7.7, 1.3Hz), 7.48 (1H, td, J = 8.5, 1.4Hz), 
6.17 (1H, s), 3.82 (3H, s), 3.13 (1H, d, J = 6.0Hz), 2.37 (1H, d, J = 6.0Hz). 13C NMR (125 MHz, CDCl3)?δ?169.6, 
148.3, 133.3, 129.8, 129.1, 124.6, 66.8, 58.1, 53.1, 51.0 ppm. IR (KBr)?δ?3648, 3093, 2957, 1725, 1440, 1357, 1267, 
1200, 1156, 1053, 947, 747 cm-1.  
syn-Methyl 2-((3-nitrophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2q. 1H NMR (500 MHz, CDCl3) δ 8.33 
(1H, m), 8.17 (1H, ddd, J = 8.2, 2.3, 1.2Hz), 7.81 (1H, m), 7.52 (1H, t, J = 7.92 Hz), 5.19 (1H, s), 3.74 (3H, s), 3.22 
(1H, d, J = 6.0Hz), 2.95 (1H, d, J = 6.0Hz). 13C NMR (125 MHz, CDCl3)?δ?169.4, 148.2, 133.3, 129.2, 123.2, 122.1, 
71.0, 65.7, 52.8, 49.7 ppm. IR (KBr)?δ?3712, 3092, 3006, 2957, 2876, 1735, 1441, 1353, 1289, 1163, 1096, 976, 935, 
866, 758 cm-1. 
syn-Methyl 2-((4-nitrophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2r. 1H NMR (500 MHz, CDCl3) δ 8.22 
(2H, d, J = 8.0Hz), 7.65 (2H, d, J = 8.0Hz), 5.13 (1H, s), 3.73 (3H, s), 3.48 (1H, d, J = 6.0Hz), 2.94 (1H, d, J = 
6.0Hz). 13C NMR (125 MHz, CDCl3)?δ?169.5, 146.0, 128.1, 127.8, 123.4, 71.4, 58.4, 53.0, 49.9 ppm. IR (KBr)?δ?
3902, 3087, 2958, 2342, 1925, 1715, 1517, 1442, 1221, 1096, 1053, 946, 777 cm-1. HRMS  m/z calcd. for 
C11H11NO6Na [M+Na+]: 276.0484, found: 276.0482. 
syn-Methyl 2-(furan-2-yl(hydroxy)methyl)oxirane-2-carboxylate 2s. 1H NMR (500 MHz, CDCl3) δ 7.38 (1H, s), 
7.26 (1H, s), 6.39 (1H, m), 6.33 (1H, m),  5.29 (1H, s), 3.75 (3H, s), 3.23 (1H, d, J = 6.0Hz), 3.05 (1H, d, J = 6.0Hz). 
13C NMR (125 MHz, CDCl3)?δ?169.3, 125.6, 142.5, 110.4, 107.7, 64.5, 52.6, 49.0 ppm. IR (KBr)?δ?3932, 3153, 
3004, 2957, 1734, 1633, 1359, 1231, 1048, 975, 753 cm-1.  
 
General experimental procedure for the preparation of cyclic carbonates: 













thiophenol (2.25 mmol). The mixture was stirred at room temperature for 15 min and then a solution of the 
epoxyester 2 (0.75 mmol) in THF (1 mL) was added drop wise and the mixture was stirred at room temperature for 
1.5 h. Then was treated with pyridine (0.22 mmol) and triphosgene (0.48 mmol). The mixture was refluxed for 15 h. 
Then brine was added and extracted with Et2O (3 x 20 mL), the organic layers were washed (brine), dried (Na2SO4), 
and concentrated. The crude oil was purified through chromatography (silica-gel, hexanes/EtOAc (8:2) and (7:3)). 
 
syn-Methyl 5-isobutyl-2-oxo-4-((phenylthio)methyl)-1,3-dioxolane-4-carboxylate 4. 1H NMR (500 MHz, CDCl3) 
δ 7.46 (2H, m), 7.25-7.33 (3H, m), 4.73 (1H, m), 3.81 (3H, s), 3.58 (1H, d, J = 15.0Hz), 3.47 (1H, d, J = 15.0Hz), 
1.77 (1H, m), 1.44 (1H, m), 1.35 (1H, m), 0.92 (3H, d, J = 6.5Hz), 0.84 (3H, d, J = 6.5Hz). 13C NMR (125 MHz, 
CDCl3)?δ?167.7, 152.7, 134.7, 131.3, 129.3, 127.7, 86.6, 80.4, 53.2, 39.6, 38.6, 25.1, 23.0, 21.2 ppm. IR (KBr)?δ?
3059, 2959, 1811, 1743, 1626, 1540, 1470, 1387, 1306, 1200, 1116, 1025, 968, 746 cm-1. HRMS  m/z calcd. for 
C16H20O5SNa [M+Na+]: 347.0929, found: 347.0929. 
anti-Methyl 5-isobutyl-2-oxo-4-((phenylthio)methyl)-1,3-dioxolane-4-carboxylate 5. 1H NMR (500 MHz, CDCl3) 
δ 7.46 (2H, m), 7.25-7.33 (3H, m), 4.76 (1H, m), 3.70 (3H, s), 3.42 (2H, s), 1.71 (1H, m), 1.49 (1H, m), 1.47 (1H, m), 
0.98 (3H, d, J = 6.5Hz), 0.95 (3H, d, J = 6.5Hz). 13C NMR (125 MHz, CDCl3)?δ?168.6, 152.2, 134.4, 131.9, 129.2, 
127.8, 85.6, 80.4, 53.4, 37.9, 37.5, 24.9, 23.2, 21.2 ppm. IR (KBr)?δ?3059, 2959, 1806, 1749, 1582, 1439, 1360, 1257, 
1132, 1048, 963, 744 cm-1. 
syn-Methyl 5-cyclohexyl-2-oxo-4-((phenylthio)methyl)-1,3-dioxolane-4-carboxylate 6. 1H NMR (500 MHz, 
CDCl3) δ 7.39 (2H, m), 7.25-7.17 (3H, m), 4.37 (1H, m), 3.73 (3H, s), 3.57 (1H, d, J = 15.0Hz), 3.35 (1H, d, J = 
15.0Hz), 1.80 (1H, m), 1.40-1.77 (5H, m), 1.24-0.79 (5H, m). 13C NMR (125 MHz, CDCl3)?δ?168.9, 152.4, 134.8, 
131.9, 129.2, 127.8, 86.0, 85.7, 53.5, 37.7, 37.3, 29.5, 28.1, 25.7, 25.4, 25.1 ppm. IR (KBr)?δ?3060, 2929, 2857, 1741, 
1582, 1402, 1195, 1024, 927, 845, 713, 629 cm-1. HRMS  m/z calcd. for C18H22O5SNa [M+Na+]: 373.1086, found: 
373.1089. 
anti-Methyl 5-cyclohexyl-2-oxo-4-((phenylthio)methyl)-1,3-dioxolane-4-carboxylate 7. 1H NMR (500 MHz, 













15.0Hz), 1.77 (1H, m), 1.68-1.76 (5H, m), 1.10-1.25 (5H, m). 13C NMR (125 MHz, CDCl3)?δ?167.9, 152.6, 134.7, 
131.7, 129.2, 127.7, 86.6, 85.8, 53.3, 40.8, 38.6, 28.6, 28.5, 25.7, 25.2, 25.0 ppm. IR (KBr)?δ?2934, 2854, 1747, 1584, 
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